Silence Therapeutics PLC (LON:SLN)

Silence Therapeutics PLC (LON:SLN)


Share Price
70.00 p
Change
0 (0.00 %)
Market Cap
£50.51 m
Proactive Investors - Run By Investors For Investors

Silence Therapeutics PLC

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by...

EPIC: SLN
Market: AIM:SLN
52-week High/Low: 175.00p / 40.00p
Sector: Pharma & Biotech
Market Cap: £50.51 m
Website: www.silence-therapeutics.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Silence Therapeutics PLC


Silence Therapeutics PLC Timeline

Silence’s group head of financial planning and analysis, Rob Quinn, will take on the outgoing David Ellam’s responsibilities for the time being whilst a permanent successor is found

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use